Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487952 | 0.69 | EPHX2 (0.46) | CYP2C9EPHX2HSD11B1CA1CA2 | |
| SCHEMBL2297553 | 0.69 | EPHX2 (0.46) | CYP2C9EPHX2HSD11B1CA1CA2 | |
| Adamantane SCHEMBL28908472 | 0.69 | CYP2C9 (0.40) | CYP2C9 | |
| Adamantane SCHEMBL29707714 | 0.68 | CYP2C9 (0.46) | CYP2C9EPHX2HSD11B1 | |
| Adamantane SCHEMBL9016497 | 0.68 | CYP2C9 (0.46) | CYP2C9EPHX2HSD11B1 | |
| Adamantane SCHEMBL12761 | 0.68 | CYP2C9 (0.46) | CYP2C9EPHX2HSD11B1 | |
| Adamantane SCHEMBL1527414 | 0.68 | CYP2C9 (0.46) | CYP2C9EPHX2HSD11B1 | |
| SCHEMBL2189873 | 0.67 | CYP2C9 (0.50) | CYP2C9EPHX2HSD11B1CYP2A13CA1 | |
| SCHEMBL3623904 | 0.67 | — | — | |
| SCHEMBL4609215 | 0.67 | CYP2C9 (0.42) | CYP2C9EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227720-A1 | DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTS | AIX-MARSEILLE UNIVERSITE (FR) | 2022-07-21 | — | — | US | claimed |
| WO-2020225330-A1 | DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTS | UNIVERSITÄT HAMBURG (DE) | 2020-11-12 | — | — | WO | claimed |
| EP-2203486-B9 | RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2012-08-01 | — | — | EP | claimed |
| US-8168556-B2 | Racemoselective synthesis of ansa-metallocene compounds, ansa-metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2012-05-01 | — | — | US | claimed |
| EP-2203486-B1 | RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2012-02-29 | — | — | EP | claimed |
| CN-101910216-A | Racemoselective synthesis of ansa-metallocene compounds, catalysts containing the same, process for preparing olefin polymers by using the catalysts and olefin homopolymers and copolymers | NOVOLEN TECH HOLDINGS CV | 2010-12-08 | — | — | CN | claimed |
| US-20100261860-A1 | RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2010-10-14 | — | — | US | claimed |
| EP-2203486-A1 | RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | Lummus Novolen Technology Gmbh (DE) | 2010-07-07 | — | — | EP | claimed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | claimed |
| WO-2010009752-A1 | CURABLE SILICONE COMPOSITIONS COMPRISING CYCLO-ALKYLPHOSPHITES | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2010-01-28 | — | — | WO | claimed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0547687-A1 | 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | claimed |
| US-4925831-A | TREATING OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED HOSTS | MERCK & CO., INC. (US) | 1990-05-15 | — | — | US | claimed |
| US-4894392-A | BACTERICIDES, FUNGICIDES, INFECTIONS | MERCK & CO., INC. (US) | 1990-01-16 | — | — | US | claimed |
| US-4217454-A | Process for stereoselectively reducing indole derivatives | ENDO LABORATORIES, INC. (US) | 1980-08-12 | — | — | US | claimed |
| US-4174453-A | HYDROGENATION, ACIDFICATION | ENDO LABORATORIES, INC. (US) | 1979-11-13 | — | — | US | claimed |
| US-3991199-A | ANALGESICS AND SEDATIVES | ENDO LABORATORIES, INC. (US) | 1976-11-09 | — | — | US | claimed |
| US-3983123-A | CNS ANTIDEPRESSANTS | ENDO LABORATORIES, INC. (US) | 1976-09-28 | — | — | US | claimed |
| US-3932650-A | TRANQUILIZERS | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | CYP2C9 142/4885EPHX2 723/4885HSD11B1 3391/4885 |
| US-20100261860-A1 | RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | MAOA, SNCA, ARSA | CYP2C9 827/4885EPHX2 4127/4885HSD11B1 385/4885 |
| US-20220227720-A1 | DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTS | DHODH, DHX15, DHX29 | CYP2C9 2890/4885EPHX2 304/4885HSD11B1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.